A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.
A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study Evaluating The Efficacy And Safety Of Latanoprost And Timolol In Pediatric Subjects With Glaucoma.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
Leuven, Belgio, 3000
- Pfizer Investigational Site
-
-
-
-
-
Praha 5, Cechia, 150 06
- Pfizer Investigational Site
-
-
-
-
Antioquia
-
Medellín, Antioquia, Colombia, 0000
- Pfizer Investigational Site
-
-
Cundinamarca
-
Bogota, Cundinamarca, Colombia, 0000
- Pfizer Investigational Site
-
-
-
-
-
Moscow, Federazione Russa, 119331
- Pfizer Investigational Site
-
St. Petersburg, Federazione Russa, 194100
- Pfizer Investigational Site
-
-
-
-
-
Makati City, Filippine, 1200
- Pfizer Investigational Site
-
Mandaluyong City, Filippine, 1500
- Pfizer Investigational Site
-
-
-
-
-
Lille Cedex, Francia, 59037
- Pfizer Investigational Site
-
Lyon, Francia, 69437
- Pfizer Investigational Site
-
-
Cedex 1
-
Amiens, Cedex 1, Francia, 80054
- Pfizer Investigational Site
-
-
-
-
-
Regenstauf, Germania, 93128
- Pfizer Investigational Site
-
Schorndorf, Germania, 73614
- Pfizer Investigational Site
-
-
-
-
Andhra Pradesh
-
Hyderabad, Andhra Pradesh, India, 500034
- Pfizer Investigational Site
-
-
Gujarat
-
Ahmedabad, Gujarat, India, 380004
- Pfizer Investigational Site
-
-
Tamilnadu
-
Coimbatore, Tamilnadu, India, 641 014
- Pfizer Investigational Site
-
-
-
-
-
Catania, Italia, 95123
- Pfizer Investigational Site
-
Milano, Italia, 20162
- Pfizer Investigational Site
-
-
-
-
-
Bialystok, Polonia, 15-274
- Pfizer Investigational Site
-
Gdansk, Polonia, 80-211
- Pfizer Investigational Site
-
Wroclaw, Polonia, 50-368
- Pfizer Investigational Site
-
-
-
-
-
Coimbra, Portogallo, 3000-548
- Pfizer Investigational Site
-
Lisboa, Portogallo, 1649-035
- Pfizer Investigational Site
-
Lisboa, Portogallo, 1169-019
- Pfizer Investigational Site
-
Lisboa, Portogallo, 1169-097
- Pfizer Investigational Site
-
Porto, Portogallo, 4099-001
- Pfizer Investigational Site
-
-
-
-
-
Birmingham, Regno Unito, B18 7QH
- Pfizer Investigational Site
-
London, Regno Unito, EC1V 2PD
- Pfizer Investigational Site
-
-
-
-
Cluj
-
Cluj-Napoca, Cluj, Romania, 400006
- Pfizer Investigational Site
-
-
-
-
-
Belgrade, Serbia, 11000
- Pfizer Investigational Site
-
-
-
-
-
Bratislava, Slovacchia, 83340
- Pfizer Investigational Site
-
-
-
-
-
Ljubljana, Slovenia, 1000
- Pfizer Investigational Site
-
-
-
-
-
Madrid, Spagna, 28040
- Pfizer Investigational Site
-
Sevilla, Spagna, 41013
- Pfizer Investigational Site
-
-
Barcelona
-
Esplugues de Llobregat, Barcelona, Spagna, 08950
- Pfizer Investigational Site
-
-
-
-
Florida
-
Pembroke Pines, Florida, Stati Uniti, 33028
- Pfizer Investigational Site
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Pfizer Investigational Site
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46202
- Pfizer Investigational Site
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55455
- Pfizer Investigational Site
-
-
Nevada
-
Henderson, Nevada, Stati Uniti, 89052
- Pfizer Investigational Site
-
Henderson, Nevada, Stati Uniti, 89074
- Pfizer Investigational Site
-
Las Vegas, Nevada, Stati Uniti, 89148
- Pfizer Investigational Site
-
-
-
-
-
Myfair West, Sud Africa, 2109
- Pfizer Investigational Site
-
-
-
-
-
Kharkiv, Ucraina, 61000
- Pfizer Investigational Site
-
Kyiv, Ucraina
- Pfizer Investigational Site
-
Kyiv, Ucraina, 04050
- Pfizer Investigational Site
-
Kyiv, Ucraina, 01135
- Pfizer Investigational Site
-
Odesa, Ucraina, 65061
- Pfizer Investigational Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Male or female of 18 years of age or under
- Diagnosis of glaucoma
- IOP of 22 mmHg or above in at least 1 eye
Exclusion Criteria:
- Require surgery for acute angle closure
- Have had prior cyclodestructive procedures
- Have a history of ocular trauma or surgery in either eye within 3 months of the baseline visit
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore attivo: Timololo
|
Timolol 0.5% dosed twice-daily
|
|
Sperimentale: latanoprost
|
Latanoprost 0.005% ophthalmic solution dosed once-daily
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Reduction From Baseline in Mean IOP at Week 12, Last Observation Carried Forward (LOCF)
Lasso di tempo: Baseline, Week 12
|
Calculated as Baseline IOP minus Week 12 IOP, LOCF.
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were less than or equal to (≤) 2 millimeters of mercury (mmHg) of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Baseline, Week 12
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Reduction From Baseline in Mean IOP at Week 1
Lasso di tempo: Baseline, Week 1
|
Calculated as Baseline IOP minus Week 1 IOP (observed).
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Baseline, Week 1
|
|
Reduction From Baseline in Mean IOP at Week 4
Lasso di tempo: Baseline, Week 4
|
Calculated as Baseline IOP minus Week 4 IOP (observed).
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Baseline, Week 4
|
|
Reduction From Baseline in Mean IOP at Week 12 (Observed)
Lasso di tempo: Baseline, Week 12
|
Calculated as Baseline IOP minus Week 12 IOP (observed).
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Baseline, Week 12
|
|
Mean IOP at Baseline
Lasso di tempo: Baseline
|
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Baseline
|
|
Mean IOP at Week 1
Lasso di tempo: Week 1
|
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Week 1
|
|
Mean IOP at Week 4
Lasso di tempo: Week 4
|
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Week 4
|
|
Mean IOP at Week 12
Lasso di tempo: Week 12
|
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Week 12
|
|
Percentage of Participants With Greater Than or Equal to (≥) 15% IOP Reduction From Baseline at Both Weeks 4 and 12
Lasso di tempo: Baseline, Week 4, and Week 12
|
Participants with ≥15% IOP reduction from baseline at both Week 4 and Week 12. Calculated as (post baseline IOP minus baseline IOP) divided by IOP, multiplied by 100%.
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Baseline, Week 4, and Week 12
|
|
Percentage of Participants Discontinuing Therapy Due to a Drug-related Adverse Experience
Lasso di tempo: Baseline through Week 12
|
An investigator's causality assessment was the determination of whether there existed a reasonable possibility that the investigational product caused or contributed to an adverse event (AE).
If the investigator did not know whether or not investigational product caused the event, then the event was handled as "related to investigational product" for reporting purposes.
|
Baseline through Week 12
|
Collaboratori e investigatori
Sponsor
Sponsor
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie degli occhi
- Ipertensione oculare
- Glaucoma
- Effetti fisiologici delle droghe
- Beta-antagonisti adrenergici
- Antagonisti adrenergici
- Agenti adrenergici
- Agenti neurotrasmettitori
- Meccanismi molecolari dell'azione farmacologica
- Agenti antiaritmici
- Agenti antipertensivi
- Soluzioni farmaceutiche
- Soluzioni oftalmiche
- Timololo
- Latanoprost
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- A6111137
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .